Active substances
Phentermine + Topiramate
- US FDA 3
- EMA 1
- US price lines 4
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| QSYMIA | EQ 3.75MG BASE;23MG; EQ 7.5MG BASE;46MG; EQ 11.25MG BASE;69MG; EQ 15MG BASE;92MG | capsule, extended release · oral | VIVUS LLC | Prescription | 17 Jul 2012 |
| PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE | EQ 3.75MG BASE;23MG; EQ 7.5MG BASE;46MG; EQ 11.25MG BASE;69MG; EQ 15MG BASE;92MG | capsule, extended release · oral | ACTAVIS LABS FL INC | Prescription | 25 Jun 2024 |
| PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE | EQ 3.75MG BASE;23MG; EQ 7.5MG BASE;46MG; EQ 11.25MG BASE;69MG; EQ 15MG BASE;92MG | capsule, extended release · oral | DR REDDYS LABS SA | Prescription | 12 Jun 2025 |
EMA European Union — centrally authorised medicines
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE | $3.09074 | per EA | 23 Sep 2026 |
| US NADAC | PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE | $2.84725 | per EA | 23 Sep 2026 |
| US NADAC | PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE | $2.98584 | per EA | 23 Sep 2026 |
| US NADAC | PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE | $3.0564 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.